UC San Diego
SCHOOL OF MEDICINE
Shiley-Marcos Alzheimer's Disease Research Center

Altman Clinical and Translational Research Institute
9500 Gilman Drive, MC 0949, La Jolla CA 92093-0949
Telephone: 858-822-4800 (ADRC main)
clinicaltrialsADRC@ucsd.edu

Studies	VIVA-MIND	Alnylam ALN-APP-001	BDNF Gene Therapy	SYN-D (Observational study)	AVANIR ASPECT AVP-786
Required Diagnosis	MCI due to Alzheimer's Disease, or mild probable **Alzheimer's Disease**	MCI or AD due to **early onset AD** (disease onset age <65, **amyloid positive**)	MCI or probable mild **AD**	Mild dementia with **Lewy bodies** or mild **AD**	Probable **Alzheimer's Disease & Clinically significant, moderate-to-severe agitation**
Phase	2A/2B	1	1	N/A	3
Route of Therapy Administration	Oral tablet	Intrathecal injection	Neurosurgery (Surgical procedure in Ohio)	N/A (non-interventional)	Oral tablet
Age	50 – 89 (inclusive)	18 and older	Minimum age 50	50 - 85	50 - 90 (inclusive)
Length	Min. of 24 wks for phase 2A. Phase 2B is planned to follow	Up to 14 months (Part A) Up to 24 months (Part B)	Overall length 2 years	12 months	Up to 14 weeks
Lumbar Puncture	Yes	10+ times	3 LPs	None	No
MRI	Required	Required	Required	No	No
Amyloid PET	No	Required	Required	One method for biomarkers	No
Tau PET	No	Optional	No	No	No
Compensation	Yes	Yes	Reimbursement for travel	Yes	Yes
Read more on clinicaltrials.gov	Identifier: NCT03919162	Identifier: NCT05231785	Identifier: NCT05040217	Identifier: NCT05479552	Identifier: NCT03393520

Required for all drug studies: Must have a study partner; No recent changes in AD medications or doses; No history of medical conditions other than the required diagnosis (e.g., AD, FTD) that could account for cognitive deficits.

FOR ALL STUDIES, PLEASE CONTACT clinicaltrialsADRC@ucsd.edu for more details

Information as of 10/18/2023